XNAS 15 Oct, 2026 10:28 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Aug 2026 | 64,953 | 64,953 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Aug 2026 | 64,953 | 32,517 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 20 Aug 2026 | 5,000 | 96,691 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 20 Aug 2026 | 5,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 4.93 per share. | 18 Aug 2026 | 10,600 | 49,100 (0%) | 0% | 4.9 | 52,258 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.72 per share. | 10 Jul 2026 | 8,059 | 9,594 (0%) | 0% | 14.7 | 118,628 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2026 | 16,667 | 17,653 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 10 Jul 2026 | 16,667 | 0 | - | - | Restricted Stock Units | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 30 Jun 2026 | 2,437 | 2,437 (0%) | 0% | 8.3 | 20,130 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 30 Jun 2026 | 2,438 | 75,563 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 30 Jun 2026 | 2,437 | 78,001 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.02 per share. | 30 Jun 2026 | 2,438 | 0 (0%) | 0% | 15.0 | 36,612 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 30 Jun 2026 | 2,437 | 2,438 (0%) | 0% | 15 | 36,555 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 30 Jun 2026 | 2,438 | 4,875 (0%) | 0% | 8.3 | 20,138 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.93 per share. | 25 May 2026 | 3,627 | 91,691 (0%) | 0% | 12.9 | 46,897 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | 25 May 2026 | 7,500 | 0 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2026 | 7,500 | 95,318 (0%) | 0% | 0 | Common Stock | |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 17 Apr 2026 | 2,437 | 2,437 (0%) | 0% | 8.3 | 20,130 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 17 Apr 2026 | 2,437 | 0 (0%) | 0% | 15 | 36,555 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 17 Apr 2026 | 2,437 | 80,438 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 23 Mar 2026 | 97,500 | 97,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 23 Mar 2026 | 97,500 | 82,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 23 Mar 2026 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Other type of transaction at price $ 13.11 per share. | 23 Mar 2026 | 76,766 | 986 (0%) | 0% | 13.1 | 1,006,402 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Other type of transaction at price $ 13.11 per share. | 23 Mar 2026 | 76,766 | 177,431 (0%) | 0% | 13.1 | 1,006,402 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 23 Mar 2026 | 52,500 | 7,800 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 13.11 per share. | 23 Mar 2026 | 76,766 | 986 (0%) | 0% | 13.1 | 1,006,402 | - |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 13.11 per share. | 23 Mar 2026 | 76,766 | 177,431 (0%) | 0% | 13.1 | 1,006,402 | - |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 13.11 per share. | 23 Mar 2026 | 76,766 | 986 (0%) | 0% | 13.1 | 1,006,402 | - |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 13.11 per share. | 23 Mar 2026 | 76,766 | 177,431 (0%) | 0% | 13.1 | 1,006,402 | - |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 13.15 per share. | 16 Mar 2026 | 1,500 | 100,665 (0%) | 0% | 13.1 | 19,724 | Common Stock |
| Dr. Jay S. Duker | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 13.15 per share. | 16 Mar 2026 | 1,500 | 100,665 (0%) | 0% | 13.1 | 19,724 | - |
| Dr. Jay S. Duker | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 13.15 per share. | 16 Mar 2026 | 1,500 | 100,665 (0%) | 0% | 13.1 | 19,724 | - |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 04 Mar 2026 | 2,438 | 82,875 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 04 Mar 2026 | 2,438 | 2,438 (0%) | 0% | 8.3 | 20,138 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 04 Mar 2026 | 2,438 | 0 (0%) | 0% | 17.9 | 43,572 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 87,818 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 87,818 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 30,000 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 87,818 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 30,000 (0%) | 0% | 0 | - | |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 17 Feb 2026 | 2,437 | 85,313 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 17 Feb 2026 | 2,437 | 2,437 (0%) | 0% | 8.3 | 20,130 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 17 Feb 2026 | 2,437 | 0 (0%) | 0% | 15 | 36,555 | Common Stock |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 75,133 | 294,346 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director | 06 Jan 2026 | 75,133 | 0 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 06 Jan 2026 | 4,487 | 91,852 (0%) | 0% | 16.9 | 75,651 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 15,285 | 96,339 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | 06 Jan 2026 | 15,285 | 0 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 06 Jan 2026 | 20,793 | 0 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 20,793 | 87,806 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 06 Jan 2026 | 10,054 | 77,752 (0%) | 0% | 16.9 | 169,510 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 15,285 | 96,339 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 06 Jan 2026 | 4,487 | 91,852 (0%) | 0% | 16.9 | 75,651 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 75,133 | 294,346 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 20,793 | 87,806 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 06 Jan 2026 | 10,054 | 77,752 (0%) | 0% | 16.9 | 169,510 | - |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 15,285 | 96,339 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 06 Jan 2026 | 4,487 | 91,852 (0%) | 0% | 16.9 | 75,651 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 75,133 | 294,346 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 20,793 | 87,806 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 06 Jan 2026 | 10,054 | 77,752 (0%) | 0% | 16.9 | 169,510 | - |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.10 per share. | 05 Jan 2026 | 42,544 | 0 (0%) | 0% | 17.1 | 727,319 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 05 Jan 2026 | 29,250 | 42,544 (0%) | 0% | 8.3 | 241,605 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 05 Jan 2026 | 29,250 | 87,750 | - | - | Stock Option (Right to Buy) | ||
| Mr. Fred Hassan | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 12,666 | 219,213 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director | 02 Jan 2026 | 12,666 | 12,667 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Goran A. Ando, M.D. | Director | 02 Jan 2026 | 41,500 | 41,500 | - | - | Stock Option (Right to Buy) | ||
| Ms. Wendy F. DiCicco | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 02 Jan 2026 | 126,000 | 126,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 02 Jan 2026 | 15,000 | 15,000 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | 02 Jan 2026 | 63,000 | 63,000 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | 02 Jan 2026 | 19,667 | 39,333 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 19,667 | 76,781 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 6,324 | 70,457 (0%) | 0% | 17.5 | 110,544 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 15,000 | 85,457 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.43 per share. | 02 Jan 2026 | 4,403 | 81,054 (0%) | 0% | 17.4 | 76,744 | Common Stock |
| Dr. John B. Landis, PhD | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Karen Zaderej | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 02 Jan 2026 | 65,000 | 130,000 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 02 Jan 2026 | 30,000 | 30,000 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 65,000 | 74,965 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 23,447 | 51,518 (0%) | 0% | 17.5 | 409,854 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 30,000 | 81,518 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.43 per share. | 02 Jan 2026 | 14,505 | 67,013 (0%) | 0% | 17.4 | 252,822 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 02 Jan 2026 | 165,000 | 165,000 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 02 Jan 2026 | 331,000 | 331,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Stuart M. Duty | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 02 Jan 2026 | 19,667 | 39,333 | - | - | Restricted Stock Units | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 19,667 | 19,667 (0%) | 0% | 0 | Common Stock | |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 6,373 | 13,294 (0%) | 0% | 17.5 | 111,400 | Common Stock |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 02 Jan 2026 | 85,700 | 85,700 | - | - | Restricted Stock Units | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 02 Jan 2026 | 171,400 | 171,400 | - | - | Stock Option (Right to Buy) | ||
| Dr. Reginald J. Sanders, M.D. | Director | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 12,666 | 219,213 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 19,667 | 76,781 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 6,324 | 70,457 (0%) | 0% | 17.5 | 110,544 | - |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 15,000 | 85,457 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.43 per share. | 02 Jan 2026 | 4,403 | 81,054 (0%) | 0% | 17.4 | 76,744 | - |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 65,000 | 74,965 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 23,447 | 51,518 (0%) | 0% | 17.5 | 409,854 | - |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 30,000 | 81,518 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.43 per share. | 02 Jan 2026 | 14,505 | 67,013 (0%) | 0% | 17.4 | 252,822 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 12,666 | 219,213 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 19,667 | 76,781 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 6,324 | 70,457 (0%) | 0% | 17.5 | 110,544 | - |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 15,000 | 85,457 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.43 per share. | 02 Jan 2026 | 4,403 | 81,054 (0%) | 0% | 17.4 | 76,744 | - |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 65,000 | 74,965 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 02 Jan 2026 | 23,447 | 51,518 (0%) | 0% | 17.5 | 409,854 | - |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 30,000 | 81,518 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.43 per share. | 02 Jan 2026 | 14,505 | 67,013 (0%) | 0% | 17.4 | 252,822 | - |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 5,000 | 57,114 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 5,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 5,000 | 57,114 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 5,000 | 25,000 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 5,000 | 57,114 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 5,000 | 25,000 (0%) | 0% | 0 | - | |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 15.11 per share. | 04 Dec 2025 | 9,300 | 206,547 (0%) | 0% | 15.1 | 140,477 | Common Stock |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 15.11 per share. | 04 Dec 2025 | 9,300 | 206,547 (0%) | 0% | 15.1 | 140,477 | - |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 15.11 per share. | 04 Dec 2025 | 9,300 | 206,547 (0%) | 0% | 15.1 | 140,477 | - |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 200 | 216,347 (0%) | 0% | 15.0 | 2,990 | Common Stock |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 500 | 215,847 (0%) | 0% | 15.0 | 7,475 | Common Stock |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 200 | 216,347 (0%) | 0% | 15.0 | 2,990 | - |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 500 | 215,847 (0%) | 0% | 15.0 | 7,475 | - |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 200 | 216,347 (0%) | 0% | 15.0 | 2,990 | - |
| Ms. Nancy S. Lurker | Director | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 26 Nov 2025 | 500 | 215,847 (0%) | 0% | 15.0 | 7,475 | - |
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.61 per share. | 11 Nov 2025 | 2,722 | 0 (0%) | 0% | 11.6 | 31,602 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2025 | 20,000 | 62,114 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2025 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2025 | 20,000 | 62,114 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2025 | 20,000 | 20,000 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2025 | 20,000 | 62,114 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2025 | 20,000 | 20,000 (0%) | 0% | 0 | - | |
| Ms. Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 2,000 | 38,500 (0%) | 0% | 0 | Common Stock | |
| Ms. Karen Zaderej | Director | 11 Jul 2025 | 2,000 | 0 | - | - | Restricted Stock Units | ||
| Ms. Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 2,000 | 38,500 (0%) | 0% | 0 | - | |
| Ms. Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 2,000 | 38,500 (0%) | 0% | 0 | - | |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 11,111 | 216,547 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director | 10 Jul 2025 | 11,111 | 11,112 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.06 per share. | 10 Jul 2025 | 7,688 | 9,965 (0%) | 0% | 11.1 | 85,029 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 16,667 | 17,653 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 10 Jul 2025 | 16,667 | 16,667 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 16,667 | 17,653 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.06 per share. | 10 Jul 2025 | 7,688 | 9,965 (0%) | 0% | 11.1 | 85,029 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 11,111 | 216,547 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 16,667 | 17,653 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.06 per share. | 10 Jul 2025 | 7,688 | 9,965 (0%) | 0% | 11.1 | 85,029 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 11,111 | 216,547 (0%) | 0% | 0 | - | |
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 15,278 | 31,944 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 31,165 | 0 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 31,165 | 213,700 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 55,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 55,000 | 200,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 103,308 | 178,442 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 103,308 | 272,358 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 15,278 | 34,722 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 27,270 | 49,730 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 02 Jul 2025 | 27,270 | 27,270 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Other type of transaction at price $ 8.21 per share. | 23 Jun 2025 | 56,665 | 986 (0%) | 0% | 8.2 | 465,220 | Common Stock |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 8.21 per share. | 23 Jun 2025 | 56,665 | 986 (0%) | 0% | 8.2 | 465,220 | - |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 8.21 per share. | 23 Jun 2025 | 56,665 | 986 (0%) | 0% | 8.2 | 465,220 | - |
| Mr. George O. Elston | Chief Financial Officer | 25 May 2025 | 7,500 | 7,500 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2025 | 7,500 | 83,050 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.68 per share. | 25 May 2025 | 2,202 | 80,848 (0%) | 0% | 5.7 | 12,507 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2025 | 7,500 | 83,050 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.68 per share. | 25 May 2025 | 2,202 | 80,848 (0%) | 0% | 5.7 | 12,507 | - |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2025 | 7,500 | 83,050 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.68 per share. | 25 May 2025 | 2,202 | 80,848 (0%) | 0% | 5.7 | 12,507 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.99 per share. | 16 May 2025 | 5,000 | 36,500 (0%) | 0% | 6.0 | 29,950 | Common Stock |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.81 per share. | 16 May 2025 | 5,000 | 31,500 (0%) | 0% | 5.8 | 29,050 | Common Stock |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.81 per share. | 16 May 2025 | 5,000 | 31,500 (0%) | 0% | 5.8 | 29,050 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.99 per share. | 16 May 2025 | 5,000 | 36,500 (0%) | 0% | 6.0 | 29,950 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.81 per share. | 16 May 2025 | 5,000 | 31,500 (0%) | 0% | 5.8 | 29,050 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.99 per share. | 16 May 2025 | 5,000 | 36,500 (0%) | 0% | 6.0 | 29,950 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 14 May 2025 | 5,000 | 21,500 (0%) | 0% | 5.4 | 27,100 | Common Stock |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.47 per share. | 14 May 2025 | 5,000 | 26,500 (0%) | 0% | 5.5 | 27,350 | Common Stock |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 14 May 2025 | 5,000 | 21,500 (0%) | 0% | 5.4 | 27,100 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.47 per share. | 14 May 2025 | 5,000 | 26,500 (0%) | 0% | 5.5 | 27,350 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 14 May 2025 | 5,000 | 21,500 (0%) | 0% | 5.4 | 27,100 | - |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.47 per share. | 14 May 2025 | 5,000 | 26,500 (0%) | 0% | 5.5 | 27,350 | - |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Other type of transaction at price $ 6.16 per share. | 19 Mar 2025 | 20,000 | 57,651 (0%) | 0% | 6.2 | 123,100 | Common Stock |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 6.16 per share. | 19 Mar 2025 | 20,000 | 57,651 (0%) | 0% | 6.2 | 123,100 | - |
| Dr. Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 6.16 per share. | 19 Mar 2025 | 20,000 | 57,651 (0%) | 0% | 6.2 | 123,100 | - |
| Ms. Nancy S. Lurker | Director | 09 Feb 2025 | 20,000 | 0 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | 09 Feb 2025 | 5,834 | 0 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 5,834 | 75,550 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 79,706 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 09 Feb 2025 | 7,000 | 0 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.49 per share. | 09 Feb 2025 | 2,055 | 77,651 (0%) | 0% | 6.5 | 13,347 | Common Stock |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 79,706 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.49 per share. | 09 Feb 2025 | 2,055 | 77,651 (0%) | 0% | 6.5 | 13,347 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 5,834 | 75,550 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 79,706 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.49 per share. | 09 Feb 2025 | 2,055 | 77,651 (0%) | 0% | 6.5 | 13,347 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 5,834 | 75,550 (0%) | 0% | 0 | - | |
| Dr. Reginald Sanders, M.D. | Director | 08 Jan 2025 | 80,000 | 80,000 | - | - | Stock Options (Right to buy) | ||
| Mr. Fred Hassan | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 03 Jan 2025 | 12,667 | 25,333 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director | 03 Jan 2025 | 75,134 | 75,133 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | Common Stock | |
| Dr. Goran A. Ando, M.D. | Director | 03 Jan 2025 | 41,500 | 41,500 | - | - | Stock Option (Right to Buy) | ||
| Ms. Wendy F. DiCicco | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 03 Jan 2025 | 15,285 | 14,715 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 63,356 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 5,267 | 58,089 (0%) | 0% | 8.3 | 43,505 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 73,374 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 4,808 | 68,566 (0%) | 0% | 8.7 | 41,733 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | 03 Jan 2025 | 59,000 | 74,000 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | 03 Jan 2025 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 03 Jan 2025 | 15,000 | 30,000 | - | - | Restricted Stock Units | ||
| Dr. John B. Landis, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 21,400 (0%) | 0% | 0 | Common Stock | |
| Dr. John B. Landis, PhD | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. John B. Landis, PhD | Director | 03 Jan 2025 | 10,000 | 0 | - | - | Restricted Stock Units | ||
| Ms. Karen Zaderej | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 10,007 | 58,020 (0%) | 0% | 8.3 | 82,658 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 78,814 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 6,108 | 72,706 (0%) | 0% | 8.7 | 53,017 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 03 Jan 2025 | 195,000 | 228,334 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 03 Jan 2025 | 390,000 | 390,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 03 Jan 2025 | 30,000 | 60,000 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 03 Jan 2025 | 20,794 | 39,206 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 68,027 (0%) | 0% | 0 | Common Stock | |
| Mr. Stuart M. Duty | Director | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 03 Jan 2025 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 03 Jan 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | - | |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 63,356 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 5,267 | 58,089 (0%) | 0% | 8.3 | 43,505 | - |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 73,374 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 4,808 | 68,566 (0%) | 0% | 8.7 | 41,733 | - |
| Dr. John B. Landis, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 21,400 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 68,027 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 10,007 | 58,020 (0%) | 0% | 8.3 | 82,658 | - |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 78,814 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 6,108 | 72,706 (0%) | 0% | 8.7 | 53,017 | - |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | - | |
| Ms. Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 63,356 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 5,267 | 58,089 (0%) | 0% | 8.3 | 43,505 | - |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 73,374 (0%) | 0% | 0 | - | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 4,808 | 68,566 (0%) | 0% | 8.7 | 41,733 | - |
| Dr. John B. Landis, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 21,400 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 68,027 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 10,007 | 58,020 (0%) | 0% | 8.3 | 82,658 | - |
| Dr. Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 78,814 (0%) | 0% | 0 | - | |
| Dr. Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 6,108 | 72,706 (0%) | 0% | 8.7 | 53,017 | - |
| Mr. Fred Hassan | Director | 03 Sep 2024 | 60,000 | 60,000 | - | - | Stock Options (Right to buy) | ||
| Dr. Goran A. Ando, M.D. | Director | Purchase of securities on an exchange or from another person at price $ 7.95 per share. | 21 Aug 2024 | 5,000 | 13,150 (0%) | 0% | 8.0 | 39,750 | Common Stock |
| Ms. Wendy F. DiCicco | Director | Purchase of securities on an exchange or from another person at price $ 7.79 per share. | 20 Aug 2024 | 2,567 | 9,967 (0%) | 0% | 7.8 | 19,997 | Common Stock |
| Ms. Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 7.98 per share. | 19 Aug 2024 | 12,500 | 16,500 (0%) | 0% | 8.0 | 99,750 | Common Stock |
| Ms. Nancy S. Lurker | Director | Purchase of securities on an exchange or from another person at price $ 7.88 per share. | 16 Aug 2024 | 3,173 | 97,635 (0%) | 0% | 7.9 | 25,003 | Common Stock |
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 1,558 | 0 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 16,666 | 16,666 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 16,666 | 50,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 56,350 | 169,050 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 56,350 | 281,750 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 30,000 | 145,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 30,000 | 95,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 26,713 | 182,535 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 26,713 | 31,165 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director | 26 Jul 2024 | 1,558 | 74,800 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 12 Jul 2024 | 11,625 | 1,850 (0%) | 0% | 10.1 | 116,995 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 12 Jul 2024 | 3,250 | 6,950 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 12 Jul 2024 | 6,525 | 13,475 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | 12 Jul 2024 | 3,250 | 3,250 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | 12 Jul 2024 | 6,525 | 6,525 | - | - | Stock Option (Right to Buy) | ||
| Ms. Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 2,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| Ms. Karen Zaderej | Director | 11 Jul 2024 | 2,000 | 2,000 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,111 | 94,462 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 10 Jul 2024 | 11,111 | 22,223 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 16,666 | 46,086 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.69 per share. | 10 Jul 2024 | 8,059 | 38,027 (0%) | 0% | 8.7 | 70,033 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 10 Jul 2024 | 16,666 | 33,334 | - | - | Restricted Stock Units | ||
| Dr. Anthony P. Adamis, M.D. | Director | 23 Jun 2024 | 2,000 | 2,000 | - | - | Restricted Stock Units | ||
| Dr. Anthony P. Adamis, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| Dr. David R. Guyer,M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 03 Jun 2024 | 6,525 | 12,075 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | 03 Jun 2024 | 6,525 | 13,050 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | 03 Jun 2024 | 3,250 | 6,500 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | Sale of securities on an exchange or to another person at price $ 10.30 per share. | 03 Jun 2024 | 11,625 | 3,700 (0%) | 0% | 10.3 | 119,705 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 03 Jun 2024 | 3,250 | 15,325 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | 25 May 2024 | 7,500 | 15,000 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.16 per share. | 25 May 2024 | 3,627 | 47,480 (0%) | 0% | 11.2 | 40,477 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 7,500 | 51,107 (0%) | 0% | 0 | Common Stock | |
| Dr. David R. Guyer,M.D. | Director | 14 May 2024 | 3,250 | 9,750 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | 14 May 2024 | 6,525 | 19,575 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 14 May 2024 | 6,525 | 13,925 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 14 May 2024 | 3,250 | 17,175 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| Dr. David R. Guyer,M.D. | Director | Sale of securities on an exchange or to another person at price $ 12.65 per share. | 14 May 2024 | 11,625 | 5,550 (0%) | 0% | 12.6 | 147,045 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 30 Mar 2024 | 5,834 | 0 | - | - | Restricted Stock Units | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.67 per share. | 30 Mar 2024 | 2,957 | 74,176 (0%) | 0% | 20.7 | 61,121 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.67 per share. | 30 Mar 2024 | 15,493 | 77,133 (0%) | 0% | 20.7 | 320,240 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 14,000 | 92,626 (0%) | 0% | 0 | Common Stock | |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 30,570 | 78,626 (0%) | 0% | 0 | Common Stock | |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.67 per share. | 30 Mar 2024 | 7,096 | 67,080 (0%) | 0% | 20.7 | 146,674 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 5,834 | 48,056 (0%) | 0% | 0 | Common Stock | |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 30 Mar 2024 | 14,000 | 0 | - | - | Restricted Stock Units | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 30 Mar 2024 | 30,570 | 0 | - | - | Restricted Stock Units | ||
| Dr. Ramiro Ribeiro, M.D.,PhD | Chief Medical Officer | 01 Mar 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Feb 2024 | 2,500 | 29,420 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Feb 2024 | 2,500 | 22,500 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2024 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2024 | 20,000 | 31,920 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 40,966 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 09 Feb 2024 | 5,833 | 5,834 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 4,452 | 155,822 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 3,116 | 1,558 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | 09 Feb 2024 | 5,833 | 5,834 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 7,000 | 50,486 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,075 | 53,378 (0%) | 0% | 28.8 | 59,760 | Common Stock |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,458 | 43,607 (0%) | 0% | 28.8 | 41,990 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 41,472 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,458 | 51,920 (0%) | 0% | 28.8 | 41,990 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 126,889 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 7,962 | 165,013 (0%) | 0% | 28.8 | 229,306 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 83,351 (0%) | 0% | 0 | Common Stock | |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 48,572 (0%) | 0% | 0 | Common Stock | |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 43,572 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 09 Feb 2024 | 7,000 | 7,000 | - | - | Restricted Stock Units | ||
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,734 | 45,065 (0%) | 0% | 28.8 | 49,939 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,701 | 44,916 (0%) | 0% | 28.8 | 48,989 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,833 | 47,305 (0%) | 0% | 0 | Common Stock | |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,565 | 42,222 (0%) | 0% | 28.8 | 73,872 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 4,452 | 57,878 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,955 | 46,617 (0%) | 0% | 28.8 | 56,304 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 3,116 | 73,242 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 6,981 | 158,032 (0%) | 0% | 28.8 | 201,053 | Common Stock |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 55,453 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 5,000 | 125,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,518 | 44,787 (0%) | 0% | 28.8 | 72,518 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 09 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 17,534 | 0 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 20,000 | 155,441 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 09 Feb 2024 | 5,000 | 115,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,833 | 46,799 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 17,534 | 172,975 (0%) | 0% | 0 | Common Stock | |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 02 Feb 2024 | 209 | 38,171 (0%) | 0% | 11.5 | 2,397 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 02 Feb 2024 | 209 | 37,962 (0%) | 0% | 28.5 | 5,954 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 02 Feb 2024 | 209 | 4,375 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.45 per share. | 26 Jan 2024 | 16,413 | 47,566 (0%) | 0% | 25.4 | 417,653 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 26 Jan 2024 | 15,609 | 70,170 (0%) | 0% | 25.4 | 396,572 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 26 Jan 2024 | 33,665 | 17,588 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 15,609 | 52,114 (0%) | 0% | 12.9 | 201,356 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 26 Jan 2024 | 16,413 | 63,979 (0%) | 0% | 3.3 | 53,506 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 26 Jan 2024 | 33,665 | 85,830 (0%) | 0% | 13.1 | 442,021 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.14 per share. | 26 Jan 2024 | 51 | 52,165 (0%) | 0% | 13.1 | 670 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 26 Jan 2024 | 51 | 51,253 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.77 per share. | 26 Jan 2024 | 33,665 | 36,505 (0%) | 0% | 25.8 | 867,672 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 9,604 | 47,566 (0%) | 0% | 12.9 | 123,892 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 26 Jan 2024 | 51 | 85,779 (0%) | 0% | 25.4 | 1,296 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.27 per share. | 26 Jan 2024 | 9,604 | 37,962 (0%) | 0% | 25.3 | 242,717 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 26 Jan 2024 | 16,413 | 68,742 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 26 Jan 2024 | 9,604 | 8,721 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 26 Jan 2024 | 15,609 | 1,026 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 25 Jan 2024 | 300 | 16,635 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 25 Jan 2024 | 300 | 51,304 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 25 Jan 2024 | 300 | 36,805 (0%) | 0% | 13.1 | 3,939 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 25 Jan 2024 | 300 | 36,505 (0%) | 0% | 25 | 7,500 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 25 Jan 2024 | 300 | 37,105 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 25 Jan 2024 | 300 | 36,805 (0%) | 0% | 25 | 7,500 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 24 Jan 2024 | 5,600 | 18,625 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,600 | 37,962 (0%) | 0% | 25.0 | 140,068 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 24 Jan 2024 | 300 | 85,155 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 5,700 | 49,262 (0%) | 0% | 3.3 | 18,582 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,700 | 43,562 (0%) | 0% | 25.0 | 142,554 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 24 Jan 2024 | 5,700 | 85,455 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 25 | 7,500 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 24 Jan 2024 | 300 | 18,325 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 37,962 (0%) | 0% | 25 | 7,500 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 5,600 | 43,562 (0%) | 0% | 12.9 | 72,240 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 300 | 38,562 (0%) | 0% | 3.3 | 978 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 23 Jan 2024 | 3,096 | 57,204 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 23 Jan 2024 | 5,651 | 42,156 (0%) | 0% | 12.9 | 72,898 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 23 Jan 2024 | 112,700 | 112,700 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 23 Jan 2024 | 3,096 | 39,601 (0%) | 0% | 13.1 | 40,650 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 23 Jan 2024 | 3,096 | 36,505 (0%) | 0% | 25 | 77,400 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 23 Jan 2024 | 5,600 | 42,156 (0%) | 0% | 25.0 | 140,052 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 23 Jan 2024 | 5,600 | 47,756 (0%) | 0% | 13.1 | 73,528 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 23 Jan 2024 | 5,600 | 51,604 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 23 Jan 2024 | 5,651 | 16,935 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 23 Jan 2024 | 2,039 | 22,586 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 23 Jan 2024 | 5,651 | 36,505 (0%) | 0% | 25.0 | 141,363 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 23 Jan 2024 | 2,039 | 39,601 (0%) | 0% | 25 | 50,975 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 23 Jan 2024 | 112,700 | 338,100 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 23 Jan 2024 | 2,039 | 41,640 (0%) | 0% | 12.9 | 26,303 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 23 Jan 2024 | 29,956 | 135,441 (0%) | 0% | 25.0 | 748,250 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 24.97 per share. | 23 Jan 2024 | 5,044 | 165,397 (0%) | 0% | 25.0 | 125,950 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 500 | 37,962 (0%) | 0% | 25 | 12,500 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 22 Jan 2024 | 400 | 38,362 (0%) | 0% | 12.9 | 5,160 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 22 Jan 2024 | 400 | 24,225 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 22 Jan 2024 | 28,750 | 37,962 (0%) | 0% | 22.7 | 652,254 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 22 Jan 2024 | 500 | 38,862 (0%) | 0% | 3.3 | 1,630 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 22 Jan 2024 | 500 | 91,155 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 22 Jan 2024 | 28,750 | 31,250 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 22 Jan 2024 | 5,416 | 72,128 (0%) | 0% | 11.5 | 62,122 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 22 Jan 2024 | 5,416 | 4,584 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.24 per share. | 22 Jan 2024 | 5,416 | 66,712 (0%) | 0% | 22.2 | 120,437 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 400 | 38,462 (0%) | 0% | 25 | 10,000 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 22 Jan 2024 | 28,750 | 66,712 (0%) | 0% | 10.1 | 291,238 | Common Stock |
| Mr. Ye Liu | Director | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 11 Jan 2024 | 1,910,500 | 100,221 (0%) | 1% | 19.5 | 37,159,225 | Common Stock, $0.001 par value |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 08 Jan 2024 | 22,913 | 59,418 (0%) | 0% | 3.3 | 74,696 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 08 Jan 2024 | 22,913 | 68,742 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.13 per share. | 08 Jan 2024 | 22,913 | 36,505 (0%) | 0% | 21.1 | 484,124 | Common Stock |
| Dr. John B. Landis, PhD | Director | 05 Jan 2024 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Wendy F. DiCicco | Director | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 05 Jan 2024 | 38,000 | 38,000 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 6,528 | 43,486 (0%) | 0% | 20.4 | 133,171 | Common Stock |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 05 Jan 2024 | 75,133 | 150,267 | - | - | Restricted Stock Units | ||
| Dr. Goran A. Ando, M.D. | Director | 05 Jan 2024 | 23,598 | 23,598 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 05 Jan 2024 | 20,793 | 41,587 | - | - | Restricted Stock Units | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,147 | 37,962 (0%) | 0% | 20.4 | 84,599 | Common Stock |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 20,793 | 50,014 (0%) | 0% | 0 | Common Stock | |
| Dr. Anthony P. Adamis, M.D. | Director | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 05 Jan 2024 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | ||
| Dr. John B. Landis, PhD | Director | 05 Jan 2024 | 10,000 | 10,000 | - | - | Restricted Stock Units | ||
| Ms. Karen Zaderej | Director | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Stuart M. Duty | Director | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 05 Jan 2024 | 45,000 | 45,000 | - | - | Restricted Stock Units | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 75,133 | 193,484 (0%) | 0% | 0 | Common Stock | |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,487 | 36,505 (0%) | 0% | 20.4 | 91,535 | Common Stock |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 05 Jan 2024 | 77,000 | 77,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 23,043 | 170,441 (0%) | 0% | 20.4 | 470,077 | Common Stock |
| Mr. David Scott Jones | SVP & Chief Commercial Officer | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | ||
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 19,628 (0%) | 0% | 0 | Common Stock | |
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 05 Jan 2024 | 90,000 | 90,000 | - | - | Restricted Stock Units | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | ||
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 5,966 | 13,662 (0%) | 0% | 20.4 | 121,706 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 40,992 (0%) | 0% | 0 | Common Stock | |
| Mr. George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,911 | 35,308 (0%) | 0% | 20.4 | 100,184 | Common Stock |
| Dr. John B. Landis, PhD | Director | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | ||
| Mr. David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 42,109 (0%) | 0% | 0 | Common Stock | |
| Dr. David R. Guyer,M.D. | Director | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 40,219 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 28 Dec 2023 | 35,000 | 130,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 52,208 | 52,208 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 28 Dec 2023 | 31,164 | 151,370 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 28 Dec 2023 | 31,164 | 62,330 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 28 Dec 2023 | 10,906 | 70,126 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 52,208 | 118,351 (0%) | 0% | 0 | Common Stock | |
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 28 Dec 2023 | 10,906 | 4,674 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 28 Dec 2023 | 35,000 | 110,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | 13 Dec 2023 | 1,458 | 37,917 | - | - | Stock Option (Right to Buy) | ||
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 13 Dec 2023 | 1,458 | 27,165 (0%) | 0% | 10.1 | 14,770 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 13 Dec 2023 | 1,458 | 25,707 (0%) | 0% | 20 | 29,160 | Common Stock |
| Mr. Ye Liu | Director | Sale of securities on an exchange or to another person at price $ 18.41 per share. | 05 Dec 2023 | 266,242 | 2,010,721 (1%) | 0% | 18.4 | 4,901,515 | Common Stock, $0.001 par value |
| Mr. Ye Liu | Director | Sale of securities on an exchange or to another person at price $ 19.91 per share. | 05 Dec 2023 | 733,758 | 2,276,963 (1%) | 0% | 19.9 | 14,609,122 | Common Stock, $0.001 par value |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | 04 Dec 2023 | 45,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 04 Dec 2023 | 20,000 | 170,559 (0%) | 0% | 20.8 | 415,200 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 30,625 | 25,707 (0%) | 0% | 22 | 673,750 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | 04 Dec 2023 | 30,625 | 39,375 | - | - | Stock Option (Right to Buy) | ||
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 04 Dec 2023 | 45,000 | 50,343 (0%) | 0% | 12.6 | 567,900 | Common Stock |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 20.79 per share. | 04 Dec 2023 | 1,000 | 4,343 (0%) | 0% | 20.8 | 20,790 | Common Stock |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 45,000 | 5,343 (0%) | 0% | 22 | 990,000 | Common Stock |
| Mr. Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 04 Dec 2023 | 30,625 | 56,332 (0%) | 0% | 10.1 | 310,231 | Common Stock |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 04 Dec 2023 | 45,000 | 50,343 (0%) | 0% | 12.6 | 567,900 | - |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 45,000 | 5,343 (0%) | 0% | 22 | 990,000 | - |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 04 Dec 2023 | 45,000 | 50,343 (0%) | 0% | 12.6 | 567,900 | - |
| Mr. Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 45,000 | 5,343 (0%) | 0% | 22 | 990,000 | - |
| Ms. Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 2,000 (0%) | 0% | 0 | Common Stock | |
| Ms. Karen Zaderej | Director | 11 Jul 2023 | 2,000 | 4,000 | - | - | Restricted Stock Units | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 10 Jul 2023 | 66,666 | 66,666 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, Executive Vice Chair | 10 Jul 2023 | 33,334 | 33,334 | - | - | Restricted Stock Units | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 10 Jul 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | ||
| Dr. Jay S. Duker, M.D. | Director, President and CEO | 10 Jul 2023 | 50,000 | 50,000 | - | - | Restricted Stock Units | ||
| Mr. Anthony P. Adamis | Director | 23 Jun 2023 | 2,000 | 4,000 | - | - | Restricted Stock Units | ||
| Mr. Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2023 | 2,000 | 2,000 (0%) | 0% | 0 | Common Stock | |
| Dr. David R. Guyer,M.D. | Director | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | ||
| Dr. David R. Guyer,M.D. | Director | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Nancy S. Lurker | Director, CEO | 20 Jun 2023 | 225,400 | 225,400 | - | - | Restricted Stock Units | ||
| Mr. Anthony P. Adamis | Director | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Anthony P. Adamis | Director | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | ||
| Dr. Goran A. Ando, M.D. | Director | 20 Jun 2023 | 27,100 | 27,100 | - | - | Stock Option (Right to Buy) | ||
| Dr. Goran A. Ando, M.D. | Director | 20 Jun 2023 | 13,500 | 13,500 | - | - | Stock Option (Right to Buy) | ||
| Ms. Wendy F. DiCicco | Director | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| Ms. Wendy F. DiCicco | Director | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | ||
| Mr. George O. Elston | Chief Financial Officer | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units |